FMP
AMEX
0.36 USD
-0.006 (-1.67%)
Mr. Jonathan Eitan Solomon MBA
Healthcare
Biotechnology
https://www.biomx.com
AMEX
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococ...
0001739174
US09090D1037
09090D103
22 Einstein Street
972 7 2394 2377
IL
54
Mar 13, 2019
0001739174
AMEX
Biotechnology
Healthcare
09090D103
US09090D1037
IL
0.36
1.22
2.72M
16.58M
-
0.187-0.855
0.35
-
-
-
-
-0.57
-
https://www.biomx.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.